Institutional crypto adoption is taking a new turn — and this time, it’s Litecoin in the spotlight.
Nasdaq-listed Mei Pharma has revealed a $100 million investment into LTC as part of its newly launched digital asset treasury strategy, according to a report from BWEnews.
The move signals growing confidence in altcoins beyond the typical Bitcoin and Ethereum plays.
While companies like MicroStrategy and Tesla have historically focused on BTC, Mei Pharma is taking a different path by positioning Litecoin at the core of its diversification plan.
This marks one of the largest corporate allocations to LTC on record, further fueling speculation that more firms may begin treating alternative cryptocurrencies as viable treasury assets.
With major players widening their exposure, the race to secure digital reserves may be entering a broader phase — and Litecoin now has a seat at the table.
Alexander Stefanov
Reporter at Coindoo
Alex is an experienced financial journalist and cryptocurrency enthusiast. With over 8 years of experience covering the crypto, blockchain, and fintech industries, he is well-versed in the complex and ever-evolving world of digital assets. His insightful and thought-provoking articles provide readers with a clear picture of the latest developments and trends in the market. His approach allows him to break down complex ideas into accessible and in-depth content. Follow his publications to stay up to date with the most important trends and topics.
Source: https://coindoo.com/this-pharma-firm-just-bet-100m-on-litecoin-heres-why-it-matters/